Name | Cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-L-cysteinyl) |
---|---|
Synonyms |
cyclo (Arg-Gly-Asp-d-Phe-Cys)
CYCLO(ARG-GLY-ASP-D-PHE-CYS)ACETATE SALT cyclo(Arg-Gly-Asp-d-Phe-Cys) Cyclo(-RGDfC), avb3 Integrin Binding Cyclic RGD Peptide CYCLO(-ARG-GLY-ASP-D-PHE-CYS) |
Description | Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) is a cyclic RGD peptide which has high affinity to αvβ3. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors[1]. |
---|---|
Related Catalog | |
Target |
αvβ3 |
In Vitro | Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5 mM, 24 h) down-regulates the transcription factors Oct 4, Sox 2 and Nanog of mESCs[1]. Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5 mM) inhibits integrin gene expression mESC-col I (type I collagen) constructs[1]. Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5 mM)-treated mESCs leads to the formation of aggregates and detachment from the surface[1]. RT-PCR[1] Cell Line: MESCs Concentration: 0.5 mM Incubation Time: 24 h Result: Down-regulated Oct 4, Nanog, Sox 2 by 99%, 97.5%, and 90% respectively. Up-regulated Rex1 gene expression. |
In Vivo | Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5 mM, 24 h)-treated mESCs in the presence/absence of LIF (injected in both thighs) generated teratomas in severe combined immunodeficiency (SCID) mice, which indicates that the process of mESC tumor formation in vivo is dependent on integrin interaction[1]. |
Molecular Formula | C24H34N8O7S |
---|---|
Molecular Weight | 578.64100 |
Exact Mass | 578.22700 |
PSA | 283.50000 |